メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
医学部・救急医学・総合内科学
藤田医科大学
医学部
概要
フィンガープリント
ネットワーク
プロファイル
(6)
研究成果
(38)
フィンガープリント
医学部・救急医学・総合内科学が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
2,3-dihydroxybenzoic Acid
15%
Acetamide
9%
Amiodarone
47%
Amnesia
47%
Aniracetam
9%
Anti-amnesic Effect
18%
AOPCP
13%
Asthma Care
18%
Asthma Specialist
28%
Bicuculline
9%
BK Channel
20%
Bradycardia
23%
Ca2+ Pump
47%
Cancer Outcomes
11%
Cardiac Contractility
23%
Cardiac Disease
7%
Cardioinhibitory
11%
Cell Remodeling
15%
Ceramide
47%
Chronic Asthma
9%
Chronic Atrial Fibrillation
7%
Chronic Hepatitis C
15%
Clinical Encounter
9%
Coronary Flow
11%
Cyclic Derivative
56%
Cycloheximide
47%
Diabetic Cardiomyopathy
10%
Diabetic Rat Heart
21%
Diacylglycerol
47%
Dimethyl
9%
Dysrhythmia
7%
Endoscopic Screening
47%
Etomoxir
47%
Fatty Acid Composition
15%
Flame Ionization Detection
47%
Flexible Sigmoidoscopy
37%
GABA Antagonist
9%
GABA Derivatives
56%
GABAA
9%
GABAA Receptor (GABAAR)
47%
GABAergic
9%
Griess Method
47%
Guaiacol
9%
Heart Function
47%
Initial Performance
9%
Initial Rhythm
9%
Intralipid
47%
Invitees
9%
Ischemia
15%
Ischemic Preconditioning
47%
Isolated Perfused Rat Heart
52%
Latency
9%
Learning Data
9%
Mechanical Signals
47%
Molecular Landscape
47%
Muscarinic ACh Receptor
18%
Muscarinic Receptors
47%
Neuronal Network
9%
No-flow
13%
Non-ischemic
10%
Non-viral
9%
Opportunistic Screening
15%
Orthovanadate
11%
Outpatient Management
18%
Passive Avoidance
9%
Performance Indicators
9%
Performance Outcomes
9%
Phenyl
9%
Picrotoxin
9%
Plasma Membrane H+-ATPase
23%
Post-cardiac Arrest Syndrome
47%
Post-occlusive Reactive Hyperemia
47%
Procedural Analgesia
47%
Procedural Sedation
47%
Program Performance
9%
Prostatic Hyperplasia
7%
Protein Kinase
10%
Protein Synthesis
9%
Public Health Insurance
9%
Radiographic Testing
39%
Reactive Hyperemia
40%
Receptor Antagonist
9%
Receptor-binding Domain
9%
Reperfusion
15%
Retention Test
9%
Ribavirin
15%
Salicylic Acid
15%
SARS-CoV-2 Pneumonia
47%
Scopolamine
9%
Severe Bradycardia
47%
Simultaneous Quantitation
47%
Sofosbuvir
47%
Solvent System
7%
Step-down
9%
Syncope
7%
Test Administration
9%
Two-dimensional Ultrasound
13%
Validation Case
9%
Vasodilatation
47%
Vasoprotective Effect
9%
Medicine and Dentistry
Acetamide
9%
Adverse Event
94%
Airway Management
8%
Airway Obstruction
47%
Amiodarone
47%
Antiviral Drug
9%
Antivirus Agent
7%
Asthma
47%
Asthma Exacerbation
21%
Bronchopneumonia
23%
Choline Acetyltransferase
47%
Chronic Atrial Fibrillation
7%
Chronic Hepatitis C
15%
Cohort Analysis
47%
COVID-19
47%
Diffuse Alveolar Damage
23%
Drug Interaction
7%
Drug Therapy
5%
Emergency Department
94%
Faintness
7%
Gamma-Aminobutyric Acid
9%
Glasgow Coma Scale
5%
Gray Matter
5%
Guaiacum
9%
Health Technology
5%
Heart Arrest
51%
High Risk Population
5%
Histopathology
23%
Hypoxemia
7%
Induced Hypothermia
47%
Infection
47%
Intensive Care Unit
47%
Intralipid
47%
Intubation
61%
Lactic Acid
5%
Logistic Regression Analysis
8%
Medical Record
5%
Mixed Infection
47%
Muscarinic Acetylcholine Receptor
47%
Nefiracetam
47%
Observational Study
100%
Odds Ratio
23%
Outpatient
10%
Pathogen
23%
Physiological Stress
11%
Pneumococcal Infection
23%
Procedural Sedation and Analgesia
47%
Prostate Hypertrophy
7%
Pulmonary Pathology
47%
Respiratory Failure
23%
Return of Spontaneous Circulation
5%
Rhythm
5%
Ribavirin
15%
Scoring System
47%
Sensitivity and Specificity
5%
Serum Albumin
5%
Severe Acute Respiratory Syndrome Coronavirus 2
47%
Sigmoidoscopy
37%
Snakebite
47%
Sofosbuvir
47%
Streptococcus Pneumoniae
47%
Technology Assessment
5%
Tracheal Intubation
56%
Pharmacology, Toxicology and Pharmaceutical Science
2,3 Dihydroxybenzoic Acid
15%
4 Aminobutyric Acid
56%
4-Aminopyridine
5%
5' Nucleotidase
5%
Acetamide
18%
Acylglycerol
7%
Adverse Event
94%
Amiodarone
47%
Aniracetam
9%
Antiviral Drug
9%
Antivirus Agent
7%
Asthma
47%
Bicuculline
9%
Binding Site
9%
Ceramide
47%
Chlorobutanol
7%
Choline Acetyltransferase
47%
Chronic Atrial Fibrillation
7%
Chronic Hepatitis C
15%
Cohort Study
47%
Colorectal Carcinoma
8%
Cycloheximide
94%
Diabetic Cardiomyopathy
7%
Diacylglycerol
94%
Drug Interaction
7%
Dyskinesia
11%
Etomoxir
47%
Faintness
7%
Fatty Acid
63%
GABA Receptor Antagonist
9%
Glasgow Coma Scale
5%
Glucose
9%
Heart Arrest
52%
Hyperaemia
47%
Hypothermia
47%
Hypoxemia
9%
Intestine Obstruction
8%
Intralipid
47%
Intubation
47%
Ischemia
31%
Lactic Acid
5%
Mongrel Dog
47%
Muscarinic Receptor
47%
Nefiracetam
47%
Nitrite
47%
Observational Study
52%
Orthovanadic Acid
7%
Picrotoxin
9%
Prostate Hypertrophy
7%
Protein Kinase C
19%
Receptor
9%
Receptor Antagonist
9%
Ribavirin
15%
Scopolamine
9%
Serum Albumin
5%
Snake Venom
11%
Snakebite
47%
Sodium Thiopental
6%
Sofosbuvir
47%
Syndrome
47%
Takotsubo Cardiomyopathy
47%
Uridine Triphosphate
7%